# Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury

> **NCT03003364** · PHASE1,PHASE2 · COMPLETED · sponsor: **Banc de Sang i Teixits** · enrollment: 10 (actual)

## Conditions studied

- Spinal Cord Injury, Chronic

## Interventions

- **DRUG:** XCEL-UMC-BETA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03003364
- **Lead sponsor:** Banc de Sang i Teixits
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-27
- **Primary completion:** 2019-07-25
- **Final completion:** 2020-02-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003364, "Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03003364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*